Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
PREVAIL Trial Efficacy and Safety | XTANDI® (enzalutamide) Safety Info
The Place of Targeted Alpha Therapy Optimizing Overall Survival in mCRPC Today and in the Future | ESMO
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
Model Simplifies mCRPC Patient Prognoses - Renal and Urology News
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Overall survival and second primary malignancies in men with metastatic prostate cancer
Overall Survival Data in mCRPC
Overall survival and second primary malignancies in men with metastatic prostate cancer
Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,' 'Tough Neighborhoods,' or 'Evil Humors'?
Clinical Parameters Predict Overall Survival in mCRPC | PracticeUpdate
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
Embarrassment of Riches: Therapies that Improve Overall Survival in mCRPC
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? - Clinical Genitourinary Cancer
ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC
Advances in Treating mCRPC: Focus on Immunotherapy
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
